<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01337167</url>
  </required_header>
  <id_info>
    <org_study_id>V419-005</org_study_id>
    <nct_id>NCT01337167</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-005)</brief_title>
  <official_title>A Phase III Randomized, Open-Label, Active-Comparator Controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V419 in Infants When Given at 2, 4, and 6 Months Concomitantly With Prevnar 13™ and RotaTeq™</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MCM Vaccines B.V.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to assess the safety, tolerability, and immunogenicity of V419 (PR5I) when
      administered as an infant series at 2, 4, and 6 months of age followed by a toddler dose of
      DAPTACEL™, Prevnar 13™ and PedvaxHIB™ at 15 months of age. The study will determine whether
      subjects who receive V419 have a similar immune response to the vaccine compared to subjects
      who receive licensed component vaccine controls.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Responding to Polyribosylribitol Phosphate Antigen</measure>
    <time_frame>Postdose 3 (Month 7)</time_frame>
    <description>Participant serum samples were collected for testing with a radioimmunoassay for antibodies to Haemophilus influenza type b capsular polysaccharide polyribosylribitol phosphate. Response was evaluated for titer &gt;=0.15 μg/mL and &gt;=1.0 μg/mL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Responding to Hepatitis B Surface Antigen</measure>
    <time_frame>Postdose 3 (Month 7)</time_frame>
    <description>Participant serum samples were collected for testing with an enhanced chemiluminescence assay for antibodies to Hepatitis B Surface Antigen. Response was defined as a titer &gt;=10 milli International units (mIU)/mL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Responding to Diphtheria Toxin</measure>
    <time_frame>Postdose 3 (Month 7)</time_frame>
    <description>Participant serum samples were collected for testing with a Micrometabolic Inhibition Test for neutralizing antibodies to diphtheria toxin. Response was defined as a titer &gt;=0.1 International unit (IU)/mL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Responding to Tetanus Toxin</measure>
    <time_frame>Postdose 3 (Month 7)</time_frame>
    <description>Participant serum samples were collected for testing with an ELISA for anti-tetanus antibodies. Response was defined as a titer &gt;=0.1 IU/mL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Responding to Pertussis Toxin</measure>
    <time_frame>Postdose 3 (Month 7)</time_frame>
    <description>Participant serum samples were collected for testing with an Enzyme-linked Immunosorbent Assay (ELISA) for antibodies to pertussis toxin. Response was defined as follows: 1) if the predose titer was &lt;4 times the lower limit of quantitation (4X LLOQ) then the postdose titer was &gt;=4X LLOQ; 2) if the predose titer was &gt;=4X LLOQ then the postdose titer was &gt;= the predose titer.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Responding to Pertussis Filamentous Hemagglutinin</measure>
    <time_frame>Postdose 3 (Month 7)</time_frame>
    <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis filamentous hemagglutinin. Response was defined as follows: 1) if the predose titer was &lt;4X LLOQ then the postdose titer was &gt;=4X LLOQ; 2) if the predose titer was &gt;=4X LLOQ then the postdose titer was &gt;= the predose titer.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Responding to Pertussis Pertactin</measure>
    <time_frame>Postdose 3 (Month 7)</time_frame>
    <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis pertactin. Response was defined as follows: 1) if the predose titer was &lt;4X LLOQ then the postdose titer was &gt;=4X LLOQ; 2) if the predose titer was &gt;=4X LLOQ then the postdose titer was &gt;= the predose titer.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Responding to Pertussis Fimbriae</measure>
    <time_frame>Postdose 3 (Month 7)</time_frame>
    <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis fimbriae. Response was defined as follows: 1) if the predose titer was &lt;4X LLOQ then the postdose titer was &gt;=4X LLOQ; 2) if the predose titer was &gt;=4X LLOQ then the postdose titer was &gt;= the predose titer.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Responding to Poliovirus Type 1</measure>
    <time_frame>Postdose 3 (Month 7)</time_frame>
    <description>Participant serum samples were collected for testing with a Micrometabolic Inhibition Test for neutralizing antibodies to Poliovirus Type 1. Response is defined as a titer &gt;=8.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Responding to Poliovirus Type 2</measure>
    <time_frame>Postdose 3 (Month 7)</time_frame>
    <description>Participant serum samples were collected for testing with a Micrometabolic Inhibition Test for neutralizing antibodies to Poliovirus Type 2. Response is defined as a titer &gt;=8.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Responding to Poliovirus Type 3</measure>
    <time_frame>Postdose 3 (Month 7)</time_frame>
    <description>Participant serum samples were collected for testing with a Micrometabolic Inhibition Test for neutralizing antibodies to Poliovirus Type 3. Response is defined as a titer &gt;=8.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Concentration of Antibodies to Pertussis Toxin</measure>
    <time_frame>Postdose 3 (Month 7)</time_frame>
    <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis toxin. The unit of measure is ELISA units/mL (EU/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Concentration of Antibodies to Pertussis Filamentous Hemagglutinin</measure>
    <time_frame>Postdose 3 (Month 7)</time_frame>
    <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis filamentous hemagglutinin.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Concentration of Antibodies to Pertussis Pertactin</measure>
    <time_frame>Postdose 3 (Month 7)</time_frame>
    <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis pertactin.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Concentration of Antibodies to Pertussis Fimbriae</measure>
    <time_frame>Postdose 3 (Month 7)</time_frame>
    <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis fimbriae.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Responding to Pertussis Toxin</measure>
    <time_frame>Postdose 4 (Month 16)</time_frame>
    <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis toxin. Response was defined as follows: 1) if the predose titer was &lt;4 times the lower limit of quantitation (4X LLOQ) then the postdose titer was &gt;=4X LLOQ; 2) if the predose titer was &gt;=4X LLOQ then the postdose titer was &gt;= the predose titer.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Responding to Pertussis Filamentous Hemagglutinin</measure>
    <time_frame>Postdose 4 (Month 16)</time_frame>
    <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis filamentous hemagglutinin. Response was defined as follows: 1) if the predose titer was &lt;4 times the lower limit of quantitation (4X LLOQ) then the postdose titer was &gt;=4X LLOQ; 2) if the predose titer was &gt;=4X LLOQ then the postdose titer was &gt;= the predose titer.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Responding to Pertussis Pertactin</measure>
    <time_frame>Postdose 4 (Month 16)</time_frame>
    <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis pertactin. Response was defined as follows: 1) if the predose titer was &lt;4 times the lower limit of quantitation (4X LLOQ) then the postdose titer was &gt;=4X LLOQ; 2) if the predose titer was &gt;=4X LLOQ then the postdose titer was &gt;= the predose titer.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Responding to Pertussis Fimbriae</measure>
    <time_frame>Postdose 4 (Month 16)</time_frame>
    <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis fimbriae. Response was defined as follows: 1) if the predose titer was &lt;4 times the lower limit of quantitation (4X LLOQ) then the postdose titer was &gt;=4X LLOQ; 2) if the predose titer was &gt;=4X LLOQ then the postdose titer was &gt;= the predose titer.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Concentration of Antibodies to Pertussis Toxin</measure>
    <time_frame>Postdose 4 (Month 16)</time_frame>
    <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis toxin.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Concentration of Antibodies to Pertussis Filamentous Hemagglutinin</measure>
    <time_frame>Postdose 4 (Month 16)</time_frame>
    <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis filamentous hemagglutinin.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Concentration of Antibodies to Pertussis Pertactin</measure>
    <time_frame>Postdose 4 (Month 16)</time_frame>
    <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis pertactin.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Concentration of Antibodies to Pertussis Fimbriae</measure>
    <time_frame>Postdose 4 (Month 16)</time_frame>
    <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis fimbriae.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentration of Antibodies to Polyribosylribitol Phosphate Antigen</measure>
    <time_frame>Postdose 3 (Month 7)</time_frame>
    <description>Participant serum samples were collected for testing with a radioimmunoassay for antibodies to Haemophilus influenza type b capsular polysaccharide polyribosylribitol phosphate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentration of Immunoglobulin A (IgA) Antibodies to Rotavirus</measure>
    <time_frame>Postdose 3 (Month 7)</time_frame>
    <description>Participant serum samples were collected for testing with an Enzyme-linked Immunosorbent assay for IgA antibodies to rotavirus.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Reporting Solicited Injection-site or Systemic Reactions</measure>
    <time_frame>Up to 5 days after any infant vaccination (up to 6 months)</time_frame>
    <description>Solicited injection-site reactions: Pain, Erythema, and Swelling. Solicited systemic reactions: Pyrexia, Vomiting, Crying abnormal, Somnolence, Decreased appetite, and Irritability. Grade 3 Solicited injection site reaction: Pain, Cries when injected limb is moved or the movement of the injected limb is reduced; Erythema and Swelling, &gt;5 cm. Grade 3 Solicited systemic reactions: Pyrexia, &gt;=39.5°C (&gt;=103.1°F) rectal; Vomiting, &gt;=6 episodes per 24 hours or requiring parenteral hydration; Crying abnormal, &gt;3 hours; Somnolence, Sleeping most of the time or difficult to wake up; Decreased appetite, Refuses &gt;=3 feeds or refuses most feeds; Irritability, Inconsolable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Reporting One or More Solicited Adverse Events Related to Study Drug</measure>
    <time_frame>Up to 5 days after any infant vaccination (up to 6 months)</time_frame>
    <description>Solicited systemic adverse events: pyrexia, vomiting, crying abnormal, somnolence, decreased appetite, and irritability. Adverse events deemed related to study drug were those judged to be definitely related, probably related, or possibly related by the investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Reporting One or More Solicited Adverse Events Related to Study Drug</measure>
    <time_frame>Up to 5 days after each infant vaccination (up to 6 months)</time_frame>
    <description>Solicited systemic adverse events: pyrexia, vomiting, crying abnormal, somnolence, decreased appetite, and irritability. Adverse events deemed related to study drug were those judged to be definitely related, probably related, or possibly related by the investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Elevated Temperature by Severity</measure>
    <time_frame>Up to 5 days after any infant vaccination (up to 6 months)</time_frame>
    <description>Maximum temperature (all routes) was based on actual temperatures recorded with no adjustments to the measurement route. Maximum temperature (rectal) was required of all participants if the reading by another method was &gt;=38.0°C.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Pyrexia, Febrile Convulsion, or Convulsion</measure>
    <time_frame>Up to 15 days after any infant vaccination (up to 6 months)</time_frame>
    <description>The percentage of participants with one or more adverse events (AE), serious adverse events (SAE), and vaccine-related SAE (pyrexia, febrile convulsion, and convulsion) is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Pyrexia, Febrile Convulsion, or Convulsion</measure>
    <time_frame>Up to 181 days after any infant vaccination (up to 12 months)</time_frame>
    <description>The percentage of participants with one or more adverse events (AE), serious adverse events (SAE), and vaccine-related SAE (pyrexia, febrile convulsion, and convulsion) is reported.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1473</enrollment>
  <condition>Bacterial Infections</condition>
  <condition>Virus Diseases</condition>
  <arm_group>
    <arm_group_label>V419</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>V419 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; PedvaxHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pentacel™ 0.5 mL IM at 2, 4, and 6 months of age; Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; ActHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V419</intervention_name>
    <description>V419 (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate [Meningococcal Outer Membrane Protein Complex], and Hepatitis B [Recombinant] Vaccine) 0.5 mL intramuscular injection at 2, 4, and 6 months of age</description>
    <arm_group_label>V419</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DAPTACEL™</intervention_name>
    <description>DAPTACEL™ 0.5 mL intramuscular injection at 15 months of age</description>
    <arm_group_label>V419</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PedvaxHIB™</intervention_name>
    <description>PedvaxHIB™ 0.5 mL intramuscular injection at 15 months of age</description>
    <arm_group_label>V419</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Prevnar 13™</intervention_name>
    <description>Prevnar 13™ 0.5 mL intramuscular injection at 2, 4, 6, and 15 months of age</description>
    <arm_group_label>V419</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RotaTeq™</intervention_name>
    <description>RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age</description>
    <arm_group_label>V419</arm_group_label>
    <arm_group_label>Control</arm_group_label>
    <other_name>V260</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PENTACEL™</intervention_name>
    <description>PENTACEL™ 0.5 mL intramuscular injection at 2, 4, and 6 months of age</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Recombivax HB vaccine</intervention_name>
    <description>Recombivax HB vaccine 0.5 mL intramuscular injection at 2 and 6 months of age</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ActHIB™</intervention_name>
    <description>ActHIB™ 0.5 mL intramuscular injection at 15 months of age</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria :

          -  Participant is a healthy infant

          -  Participant has received one dose of monovalent hepatitis B vaccine prior to or at 1
             month of age

        Exclusion Criteria :

          -  Participant has received more than one dose of monovalent hepatitis B vaccine or
             hepatitis B based combination vaccine prior to study entry

          -  Participant has been vaccinated with any acellular pertussis or whole cell pertussis
             based combination vaccines, haemophilus influenzae type b conjugate, poliovirus,
             pneumococcal conjugate or pneumococcal polysaccharide, rotavirus, or any combination
             of the above

          -  Participant has had a fever ≥38.0°C (≥110.4°F) within 24 hours of study enrollment

          -  Participant was vaccinated with any non-study vaccine (i.e., inactivated, conjugated,
             live virus vaccine) within 30 days prior to study enrollment, except for inactivated
             influenza vaccine which will be permitted 15 days or more prior to enrollment

          -  Participant has hepatitis B surface antigen (HBsAg) seropositivity (by medical
             history)

          -  Participant has a history of haemophilus influenzae type B, hepatitis B, diphtheria,
             tetanus, pertussis, poliomyelitis, rotavirus, or pneumococcal infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>46 Days</minimum_age>
    <maximum_age>89 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <reference>
    <citation>Marshall GS, Adams GL, Leonardi ML, Petrecz M, Flores SA, Ngai AL, Xu J, Liu G, Stek JE, Foglia G, Lee AW. Immunogenicity, Safety, and Tolerability of a Hexavalent Vaccine in Infants. Pediatrics. 2015 Aug;136(2):e323-32. doi: 10.1542/peds.2014-4102.</citation>
    <PMID>26216331</PMID>
  </reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2011</study_first_submitted>
  <study_first_submitted_qc>April 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2011</study_first_posted>
  <results_first_submitted>February 18, 2016</results_first_submitted>
  <results_first_submitted_qc>February 18, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 16, 2016</results_first_posted>
  <last_update_submitted>February 18, 2016</last_update_submitted>
  <last_update_submitted_qc>February 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diphtheria</keyword>
  <keyword>Tetanus</keyword>
  <keyword>Whooping Cough (pertussis)</keyword>
  <keyword>Poliomyelitis</keyword>
  <keyword>Hepatitis B infection</keyword>
  <keyword>Haemophilus influenzae type b infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Bacterial Infections</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The infant series of vaccinations were those administered at 2, 4, and 6 months of age; the toddler vaccinations were those administered at 15 months of age. The Interim Period is the time between the last vaccination of the infant series and the time of administration of the toddler vaccination.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>V419</title>
          <description>V419 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; PedvaxHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>Pentacel™ 0.5 mL IM at 2, 4, and 6 months of age; Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; ActHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Infant Series</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="986"/>
                <participants group_id="P2" count="487"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="924"/>
                <participants group_id="P2" count="460"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with study drug</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized but not vaccinated</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Interim Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="924"/>
                <participants group_id="P2" count="460"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="843"/>
                <participants group_id="P2" count="420"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="81"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with study drug</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other protocol criterion not met</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Toddler Vaccinations</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="843"/>
                <participants group_id="P2" count="420"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="829"/>
                <participants group_id="P2" count="407"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>V419</title>
          <description>V419 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; PedvaxHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>Pentacel™ 0.5 mL IM at 2, 4, and 6 months of age; Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; ActHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="986"/>
            <count group_id="B2" value="487"/>
            <count group_id="B3" value="1473"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.6" spread="7.5"/>
                    <measurement group_id="B2" value="65.0" spread="6.9"/>
                    <measurement group_id="B3" value="65.4" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="479"/>
                    <measurement group_id="B2" value="214"/>
                    <measurement group_id="B3" value="693"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="507"/>
                    <measurement group_id="B2" value="273"/>
                    <measurement group_id="B3" value="780"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Responding to Polyribosylribitol Phosphate Antigen</title>
        <description>Participant serum samples were collected for testing with a radioimmunoassay for antibodies to Haemophilus influenza type b capsular polysaccharide polyribosylribitol phosphate. Response was evaluated for titer &gt;=0.15 μg/mL and &gt;=1.0 μg/mL.</description>
        <time_frame>Postdose 3 (Month 7)</time_frame>
        <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had a vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
        <group_list>
          <group group_id="O1">
            <title>V419</title>
            <description>V419 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; PedvaxHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Pentacel™ 0.5 mL IM at 2, 4, and 6 months of age; Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; ActHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Responding to Polyribosylribitol Phosphate Antigen</title>
          <description>Participant serum samples were collected for testing with a radioimmunoassay for antibodies to Haemophilus influenza type b capsular polysaccharide polyribosylribitol phosphate. Response was evaluated for titer &gt;=0.15 μg/mL and &gt;=1.0 μg/mL.</description>
          <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had a vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="765"/>
                <count group_id="O2" value="382"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Titer &gt;=1.0 μg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.97" lower_limit="82.24" upper_limit="87.43"/>
                    <measurement group_id="O2" value="75.39" lower_limit="70.76" upper_limit="79.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Titer &gt;=0.15 μg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.25" lower_limit="95.83" upper_limit="98.29"/>
                    <measurement group_id="O2" value="92.41" lower_limit="89.28" upper_limit="94.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority for titer &gt;=1.0 μg/mL</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority requires that the lower limit of the 95% CI of the response rate difference is &gt;= -10%</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>Response rate, response rate difference and p-value were stratified by brand of birth dose of Hepatitis B vaccine</method_desc>
            <param_type>Response Rate Difference (V419 - Ctrl)</param_type>
            <param_value>9.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.83</ci_lower_limit>
            <ci_upper_limit>14.83</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority for titer &gt;=0.15 μg/mL</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority requires that the lower limit of the 95% CI of the response rate difference is &gt;= -5%</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>Response rate, response rate difference and p-value were stratified by brand of birth dose of Hepatitis B vaccine</method_desc>
            <param_type>Response Rate Difference (V419 - Ctrl)</param_type>
            <param_value>4.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.23</ci_lower_limit>
            <ci_upper_limit>8.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Secondary Analysis: Non-inferiority for titer &gt;=0.15 μg/mL</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority requires that the lower limit of the 95% CI of the response rate difference is &gt;= -10%</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>Response rate, response rate difference and p-value were stratified by brand of birth dose of Hepatitis B vaccine</method_desc>
            <param_type>Response Rate Difference (V419-Ctrl)</param_type>
            <param_value>4.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.23</ci_lower_limit>
            <ci_upper_limit>8.14</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Responding to Hepatitis B Surface Antigen</title>
        <description>Participant serum samples were collected for testing with an enhanced chemiluminescence assay for antibodies to Hepatitis B Surface Antigen. Response was defined as a titer &gt;=10 milli International units (mIU)/mL.</description>
        <time_frame>Postdose 3 (Month 7)</time_frame>
        <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had a vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
        <group_list>
          <group group_id="O1">
            <title>V419</title>
            <description>V419 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; PedvaxHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Pentacel™ 0.5 mL IM at 2, 4, and 6 months of age; Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; ActHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Responding to Hepatitis B Surface Antigen</title>
          <description>Participant serum samples were collected for testing with an enhanced chemiluminescence assay for antibodies to Hepatitis B Surface Antigen. Response was defined as a titer &gt;=10 milli International units (mIU)/mL.</description>
          <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had a vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="688"/>
                <count group_id="O2" value="353"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.42" lower_limit="98.52" upper_limit="99.84"/>
                    <measurement group_id="O2" value="98.58" lower_limit="96.73" upper_limit="99.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority requires that the lower limit of the 95% CI of the response rate difference is &gt;= -10%</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>Response rate, response rate difference and p-value were stratified by brand of birth dose of Hepatitis B vaccine</method_desc>
            <param_type>Response Rate Difference (V419 - Ctrl)</param_type>
            <param_value>0.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.35</ci_lower_limit>
            <ci_upper_limit>2.74</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Responding to Diphtheria Toxin</title>
        <description>Participant serum samples were collected for testing with a Micrometabolic Inhibition Test for neutralizing antibodies to diphtheria toxin. Response was defined as a titer &gt;=0.1 International unit (IU)/mL.</description>
        <time_frame>Postdose 3 (Month 7)</time_frame>
        <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had a vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
        <group_list>
          <group group_id="O1">
            <title>V419</title>
            <description>V419 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; PedvaxHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Pentacel™ 0.5 mL IM at 2, 4, and 6 months of age; Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; ActHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Responding to Diphtheria Toxin</title>
          <description>Participant serum samples were collected for testing with a Micrometabolic Inhibition Test for neutralizing antibodies to diphtheria toxin. Response was defined as a titer &gt;=0.1 International unit (IU)/mL.</description>
          <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had a vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="786"/>
                <count group_id="O2" value="393"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.44" lower_limit="79.60" upper_limit="85.04"/>
                    <measurement group_id="O2" value="86.26" lower_limit="82.45" upper_limit="89.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority requires that the lower limit of the 95% CI of the response rate difference is &gt;= -10%</non_inferiority_desc>
            <p_value>0.002</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>Response rate, response rate difference and p-value were stratified by brand of birth dose of Hepatitis B vaccine</method_desc>
            <param_type>Response Rate Difference (V419 - Ctrl)</param_type>
            <param_value>-3.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.02</ci_lower_limit>
            <ci_upper_limit>0.66</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Responding to Tetanus Toxin</title>
        <description>Participant serum samples were collected for testing with an ELISA for anti-tetanus antibodies. Response was defined as a titer &gt;=0.1 IU/mL.</description>
        <time_frame>Postdose 3 (Month 7)</time_frame>
        <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had a vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
        <group_list>
          <group group_id="O1">
            <title>V419</title>
            <description>V419 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; PedvaxHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Pentacel™ 0.5 mL IM at 2, 4, and 6 months of age; Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; ActHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Responding to Tetanus Toxin</title>
          <description>Participant serum samples were collected for testing with an ELISA for anti-tetanus antibodies. Response was defined as a titer &gt;=0.1 IU/mL.</description>
          <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had a vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="787"/>
                <count group_id="O2" value="390"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.87" lower_limit="99.29" upper_limit="100.00"/>
                    <measurement group_id="O2" value="99.49" lower_limit="98.16" upper_limit="99.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority requires that the lower limit of the 95% CI of the response rate difference is &gt;= -5%</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>Response rate, response rate difference and p-value were stratified by brand of birth dose of Hepatitis B vaccine</method_desc>
            <param_type>Response Rate Difference (V419 - Ctrl)</param_type>
            <param_value>0.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.28</ci_lower_limit>
            <ci_upper_limit>1.74</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Responding to Pertussis Toxin</title>
        <description>Participant serum samples were collected for testing with an Enzyme-linked Immunosorbent Assay (ELISA) for antibodies to pertussis toxin. Response was defined as follows: 1) if the predose titer was &lt;4 times the lower limit of quantitation (4X LLOQ) then the postdose titer was &gt;=4X LLOQ; 2) if the predose titer was &gt;=4X LLOQ then the postdose titer was &gt;= the predose titer.</description>
        <time_frame>Postdose 3 (Month 7)</time_frame>
        <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had a vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
        <group_list>
          <group group_id="O1">
            <title>V419</title>
            <description>V419 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; PedvaxHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Pentacel™ 0.5 mL IM at 2, 4, and 6 months of age; Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; ActHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Responding to Pertussis Toxin</title>
          <description>Participant serum samples were collected for testing with an Enzyme-linked Immunosorbent Assay (ELISA) for antibodies to pertussis toxin. Response was defined as follows: 1) if the predose titer was &lt;4 times the lower limit of quantitation (4X LLOQ) then the postdose titer was &gt;=4X LLOQ; 2) if the predose titer was &gt;=4X LLOQ then the postdose titer was &gt;= the predose titer.</description>
          <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had a vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="796"/>
                <count group_id="O2" value="391"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.12" lower_limit="96.91" upper_limit="98.94"/>
                    <measurement group_id="O2" value="98.47" lower_limit="96.69" upper_limit="99.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority requires that the lower limit of the 95% CI of the response rate difference is &gt;= -10%</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>Response rate, response rate difference and p-value were stratified by brand of birth dose of Hepatitis B vaccine</method_desc>
            <param_type>Response Rate Difference (V419 - Ctrl)</param_type>
            <param_value>-0.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.80</ci_lower_limit>
            <ci_upper_limit>1.60</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Responding to Pertussis Filamentous Hemagglutinin</title>
        <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis filamentous hemagglutinin. Response was defined as follows: 1) if the predose titer was &lt;4X LLOQ then the postdose titer was &gt;=4X LLOQ; 2) if the predose titer was &gt;=4X LLOQ then the postdose titer was &gt;= the predose titer.</description>
        <time_frame>Postdose 3 (Month 7)</time_frame>
        <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had a vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
        <group_list>
          <group group_id="O1">
            <title>V419</title>
            <description>V419 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; PedvaxHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Pentacel™ 0.5 mL IM at 2, 4, and 6 months of age; Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; ActHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Responding to Pertussis Filamentous Hemagglutinin</title>
          <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis filamentous hemagglutinin. Response was defined as follows: 1) if the predose titer was &lt;4X LLOQ then the postdose titer was &gt;=4X LLOQ; 2) if the predose titer was &gt;=4X LLOQ then the postdose titer was &gt;= the predose titer.</description>
          <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had a vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="796"/>
                <count group_id="O2" value="391"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.31" lower_limit="84.80" upper_limit="89.55"/>
                    <measurement group_id="O2" value="92.07" lower_limit="88.93" upper_limit="94.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority requires that the lower limit of the 95% CI of the response rate difference is &gt;= -10%</non_inferiority_desc>
            <p_value>0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>Response rate, response rate difference and p-value were stratified by brand of birth dose of Hepatitis B vaccine</method_desc>
            <param_type>Response Rate Difference (V419 - Ctrl)</param_type>
            <param_value>-4.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.14</ci_lower_limit>
            <ci_upper_limit>-0.97</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Responding to Pertussis Pertactin</title>
        <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis pertactin. Response was defined as follows: 1) if the predose titer was &lt;4X LLOQ then the postdose titer was &gt;=4X LLOQ; 2) if the predose titer was &gt;=4X LLOQ then the postdose titer was &gt;= the predose titer.</description>
        <time_frame>Postdose 3 (Month 7)</time_frame>
        <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had a vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
        <group_list>
          <group group_id="O1">
            <title>V419</title>
            <description>V419 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; PedvaxHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Pentacel™ 0.5 mL IM at 2, 4, and 6 months of age; Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; ActHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Responding to Pertussis Pertactin</title>
          <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis pertactin. Response was defined as follows: 1) if the predose titer was &lt;4X LLOQ then the postdose titer was &gt;=4X LLOQ; 2) if the predose titer was &gt;=4X LLOQ then the postdose titer was &gt;= the predose titer.</description>
          <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had a vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="794"/>
                <count group_id="O2" value="390"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.35" lower_limit="76.36" upper_limit="82.11"/>
                    <measurement group_id="O2" value="82.05" lower_limit="77.88" upper_limit="85.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority requires that the lower limit of the 95% CI of the response rate difference is &gt;= -10%</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>Response rate, response rate difference and p-value were stratified by brand of birth dose of Hepatitis B vaccine</method_desc>
            <param_type>Response Rate Difference (V419 - Ctrl)</param_type>
            <param_value>-2.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.27</ci_lower_limit>
            <ci_upper_limit>2.23</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Responding to Pertussis Fimbriae</title>
        <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis fimbriae. Response was defined as follows: 1) if the predose titer was &lt;4X LLOQ then the postdose titer was &gt;=4X LLOQ; 2) if the predose titer was &gt;=4X LLOQ then the postdose titer was &gt;= the predose titer.</description>
        <time_frame>Postdose 3 (Month 7)</time_frame>
        <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had a vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
        <group_list>
          <group group_id="O1">
            <title>V419</title>
            <description>V419 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; PedvaxHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Pentacel™ 0.5 mL IM at 2, 4, and 6 months of age; Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; ActHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Responding to Pertussis Fimbriae</title>
          <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis fimbriae. Response was defined as follows: 1) if the predose titer was &lt;4X LLOQ then the postdose titer was &gt;=4X LLOQ; 2) if the predose titer was &gt;=4X LLOQ then the postdose titer was &gt;= the predose titer.</description>
          <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had a vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="796"/>
                <count group_id="O2" value="391"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.20" lower_limit="87.92" upper_limit="92.18"/>
                    <measurement group_id="O2" value="86.19" lower_limit="82.37" upper_limit="89.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority requires that the lower limit of the 95% CI of the response rate difference is &gt;= -10%</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>Response rate, response rate difference and p-value were stratified by brand of birth dose of Hepatitis B vaccine</method_desc>
            <param_type>Response Rate Difference (V419 - Ctrl)</param_type>
            <param_value>4.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.23</ci_lower_limit>
            <ci_upper_limit>8.28</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Responding to Poliovirus Type 1</title>
        <description>Participant serum samples were collected for testing with a Micrometabolic Inhibition Test for neutralizing antibodies to Poliovirus Type 1. Response is defined as a titer &gt;=8.</description>
        <time_frame>Postdose 3 (Month 7)</time_frame>
        <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had a vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
        <group_list>
          <group group_id="O1">
            <title>V419</title>
            <description>V419 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; PedvaxHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Pentacel™ 0.5 mL IM at 2, 4, and 6 months of age; Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; ActHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Responding to Poliovirus Type 1</title>
          <description>Participant serum samples were collected for testing with a Micrometabolic Inhibition Test for neutralizing antibodies to Poliovirus Type 1. Response is defined as a titer &gt;=8.</description>
          <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had a vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="806"/>
                <count group_id="O2" value="398"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00" lower_limit="99.54" upper_limit="100.00"/>
                    <measurement group_id="O2" value="98.24" lower_limit="96.41" upper_limit="99.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority requires that the lower limit of the 95% CI of the response rate difference is &gt;= -5%</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>Response rate, response rate difference and p-value were stratified by brand of birth dose of Hepatitis B vaccine</method_desc>
            <param_type>Response Rate Difference (V419 - Ctrl)</param_type>
            <param_value>1.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>3.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Clopper and Pearson</method>
            <method_desc>Acceptability requires that the lower bound of the 2-sided 95% CI of the response rate is &gt;=90</method_desc>
            <param_type>Response Rate</param_type>
            <param_value>100.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>99.54</ci_lower_limit>
            <ci_upper_limit>100.00</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Responding to Poliovirus Type 2</title>
        <description>Participant serum samples were collected for testing with a Micrometabolic Inhibition Test for neutralizing antibodies to Poliovirus Type 2. Response is defined as a titer &gt;=8.</description>
        <time_frame>Postdose 3 (Month 7)</time_frame>
        <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had a vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
        <group_list>
          <group group_id="O1">
            <title>V419</title>
            <description>V419 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; PedvaxHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Pentacel™ 0.5 mL IM at 2, 4, and 6 months of age; Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; ActHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Responding to Poliovirus Type 2</title>
          <description>Participant serum samples were collected for testing with a Micrometabolic Inhibition Test for neutralizing antibodies to Poliovirus Type 2. Response is defined as a titer &gt;=8.</description>
          <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had a vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="801"/>
                <count group_id="O2" value="399"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00" lower_limit="99.54" upper_limit="100.00"/>
                    <measurement group_id="O2" value="99.75" lower_limit="98.61" upper_limit="99.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority requires that the lower limit of the 95% CI of the response rate difference is &gt;= -5%</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>Response rate, response rate difference and p-value were stratified by brand of birth dose of Hepatitis B vaccine</method_desc>
            <param_type>Response Rate Difference (V419 - Ctrl)</param_type>
            <param_value>0.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.22</ci_lower_limit>
            <ci_upper_limit>1.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Clopper and Pearson</method>
            <method_desc>Acceptability requires that the lower bound of the 2-sided 95% CI of the response rate is &gt;=90</method_desc>
            <param_type>Response Rate</param_type>
            <param_value>100.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>99.54</ci_lower_limit>
            <ci_upper_limit>100.00</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Responding to Poliovirus Type 3</title>
        <description>Participant serum samples were collected for testing with a Micrometabolic Inhibition Test for neutralizing antibodies to Poliovirus Type 3. Response is defined as a titer &gt;=8.</description>
        <time_frame>Postdose 3 (Month 7)</time_frame>
        <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had a vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
        <group_list>
          <group group_id="O1">
            <title>V419</title>
            <description>V419 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; PedvaxHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Pentacel™ 0.5 mL IM at 2, 4, and 6 months of age; Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; ActHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Responding to Poliovirus Type 3</title>
          <description>Participant serum samples were collected for testing with a Micrometabolic Inhibition Test for neutralizing antibodies to Poliovirus Type 3. Response is defined as a titer &gt;=8.</description>
          <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had a vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="790"/>
                <count group_id="O2" value="396"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00" lower_limit="99.53" upper_limit="100.00"/>
                    <measurement group_id="O2" value="99.75" lower_limit="98.60" upper_limit="99.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority requires that the lower limit of the 95% CI of the response rate difference is &gt;= -5%</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>Response rate, response rate difference and p-value were stratified by brand of birth dose of Hepatitis B vaccine</method_desc>
            <param_type>Response Rate Difference (V419 - Ctrl)</param_type>
            <param_value>0.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.24</ci_lower_limit>
            <ci_upper_limit>1.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Clopper and Pearson</method>
            <method_desc>Acceptability requires that the lower bound of the 2-sided 95% CI of the response rate is &gt;=90</method_desc>
            <param_type>Response Rate</param_type>
            <param_value>100.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>99.53</ci_lower_limit>
            <ci_upper_limit>100.00</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Concentration of Antibodies to Pertussis Toxin</title>
        <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis toxin. The unit of measure is ELISA units/mL (EU/mL).</description>
        <time_frame>Postdose 3 (Month 7)</time_frame>
        <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had an infant vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
        <group_list>
          <group group_id="O1">
            <title>V419</title>
            <description>V419 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; PedvaxHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Pentacel™ 0.5 mL IM at 2, 4, and 6 months of age; Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; ActHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration of Antibodies to Pertussis Toxin</title>
          <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis toxin. The unit of measure is ELISA units/mL (EU/mL).</description>
          <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had an infant vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
          <units>EU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="810"/>
                <count group_id="O2" value="400"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110.40" lower_limit="105.78" upper_limit="115.21"/>
                    <measurement group_id="O2" value="86.54" lower_limit="81.87" upper_limit="91.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority requires that the lower limit of the 2-sided 95% CI of the Geometric Mean Concentration (GMC) ratio is &gt;=0.67</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>GMC, GMC ratio, and p-value were adjusted for post- and prevaccination titer, vaccination group, and brand of birth dose of Hepatitis B vaccine</method_desc>
            <param_type>GMC Ratio (V419/Control)</param_type>
            <param_value>1.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.20</ci_lower_limit>
            <ci_upper_limit>1.38</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Concentration of Antibodies to Pertussis Filamentous Hemagglutinin</title>
        <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis filamentous hemagglutinin.</description>
        <time_frame>Postdose 3 (Month 7)</time_frame>
        <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had an infant vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
        <group_list>
          <group group_id="O1">
            <title>V419</title>
            <description>V419 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; PedvaxHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Pentacel™ 0.5 mL IM at 2, 4, and 6 months of age; Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; ActHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration of Antibodies to Pertussis Filamentous Hemagglutinin</title>
          <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis filamentous hemagglutinin.</description>
          <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had an infant vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
          <units>EU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="810"/>
                <count group_id="O2" value="400"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.17" lower_limit="45.68" upper_limit="50.80"/>
                    <measurement group_id="O2" value="74.44" lower_limit="68.99" upper_limit="80.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority requires that the lower limit of the 2-sided 95% CI of the GMC ratio is &gt;=0.67</non_inferiority_desc>
            <p_value>0.786</p_value>
            <method>ANCOVA</method>
            <method_desc>GMC, GMC ratio, and p-value were adjusted for post- and prevaccination titer, vaccination group, and brand of birth dose of Hepatitis B vaccine</method_desc>
            <param_type>GMC Ratio (V419/Control)</param_type>
            <param_value>0.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>0.70</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Concentration of Antibodies to Pertussis Pertactin</title>
        <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis pertactin.</description>
        <time_frame>Postdose 3 (Month 7)</time_frame>
        <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had an infant vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
        <group_list>
          <group group_id="O1">
            <title>V419</title>
            <description>V419 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; PedvaxHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Pentacel™ 0.5 mL IM at 2, 4, and 6 months of age; Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; ActHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration of Antibodies to Pertussis Pertactin</title>
          <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis pertactin.</description>
          <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had an infant vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
          <units>EU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="808"/>
                <count group_id="O2" value="400"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.22" lower_limit="51.93" upper_limit="60.85"/>
                    <measurement group_id="O2" value="66.16" lower_limit="59.50" upper_limit="73.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority requires that the lower limit of the 2-sided 95% CI of the GMC ratio is &gt;=0.67</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>GMC, GMC ratio, and p-value were adjusted for post- and prevaccination titer, vaccination group, and brand of birth dose of Hepatitis B vaccine</method_desc>
            <param_type>GMC Ratio (V419/Control)</param_type>
            <param_value>0.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>0.95</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Concentration of Antibodies to Pertussis Fimbriae</title>
        <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis fimbriae.</description>
        <time_frame>Postdose 3 (Month 7)</time_frame>
        <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had an infant vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
        <group_list>
          <group group_id="O1">
            <title>V419</title>
            <description>V419 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; PedvaxHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Pentacel™ 0.5 mL IM at 2, 4, and 6 months of age; Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; ActHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration of Antibodies to Pertussis Fimbriae</title>
          <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis fimbriae.</description>
          <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had an infant vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
          <units>EU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="809"/>
                <count group_id="O2" value="400"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="235.62" lower_limit="221.43" upper_limit="250.73"/>
                    <measurement group_id="O2" value="185.54" lower_limit="169.33" upper_limit="203.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority requires that the lower limit of the 2-sided 95% CI of the GMC ratio is &gt;=0.67</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>GMC, GMC ratio, and p-value were adjusted for post- and prevaccination titer, vaccination group, and brand of birth dose of Hepatitis B vaccine</method_desc>
            <param_type>GMC Ratio (V419/Control)</param_type>
            <param_value>1.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.15</ci_lower_limit>
            <ci_upper_limit>1.42</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Responding to Pertussis Toxin</title>
        <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis toxin. Response was defined as follows: 1) if the predose titer was &lt;4 times the lower limit of quantitation (4X LLOQ) then the postdose titer was &gt;=4X LLOQ; 2) if the predose titer was &gt;=4X LLOQ then the postdose titer was &gt;= the predose titer.</description>
        <time_frame>Postdose 4 (Month 16)</time_frame>
        <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had a vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 4.</population>
        <group_list>
          <group group_id="O1">
            <title>V419</title>
            <description>V419 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; PedvaxHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Pentacel™ 0.5 mL IM at 2, 4, and 6 months of age; Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; ActHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Responding to Pertussis Toxin</title>
          <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis toxin. Response was defined as follows: 1) if the predose titer was &lt;4 times the lower limit of quantitation (4X LLOQ) then the postdose titer was &gt;=4X LLOQ; 2) if the predose titer was &gt;=4X LLOQ then the postdose titer was &gt;= the predose titer.</description>
          <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had a vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 4.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="701"/>
                <count group_id="O2" value="349"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.29" lower_limit="98.34" upper_limit="99.77"/>
                    <measurement group_id="O2" value="97.42" lower_limit="95.16" upper_limit="98.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority requires that the lower limit of the 95% CI of the response rate difference is &gt;= -10%</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>Response rate, response rate difference and p-value were stratified by brand of birth dose of Hepatitis B vaccine</method_desc>
            <param_type>Response Rate Difference (V419 - Ctrl)</param_type>
            <param_value>1.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.39</ci_lower_limit>
            <ci_upper_limit>4.18</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Responding to Pertussis Filamentous Hemagglutinin</title>
        <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis filamentous hemagglutinin. Response was defined as follows: 1) if the predose titer was &lt;4 times the lower limit of quantitation (4X LLOQ) then the postdose titer was &gt;=4X LLOQ; 2) if the predose titer was &gt;=4X LLOQ then the postdose titer was &gt;= the predose titer.</description>
        <time_frame>Postdose 4 (Month 16)</time_frame>
        <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had a vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 4.</population>
        <group_list>
          <group group_id="O1">
            <title>V419</title>
            <description>V419 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; PedvaxHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Pentacel™ 0.5 mL IM at 2, 4, and 6 months of age; Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; ActHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Responding to Pertussis Filamentous Hemagglutinin</title>
          <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis filamentous hemagglutinin. Response was defined as follows: 1) if the predose titer was &lt;4 times the lower limit of quantitation (4X LLOQ) then the postdose titer was &gt;=4X LLOQ; 2) if the predose titer was &gt;=4X LLOQ then the postdose titer was &gt;= the predose titer.</description>
          <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had a vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 4.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="699"/>
                <count group_id="O2" value="350"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.42" lower_limit="92.45" upper_limit="96.00"/>
                    <measurement group_id="O2" value="93.14" lower_limit="89.97" upper_limit="95.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority requires that the lower limit of the 95% CI of the response rate difference is &gt;= -10%</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>Response rate, response rate difference and p-value were stratified by brand of birth dose of Hepatitis B vaccine</method_desc>
            <param_type>Response Rate Difference (V419 - Ctrl)</param_type>
            <param_value>1.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.67</ci_lower_limit>
            <ci_upper_limit>4.78</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Responding to Pertussis Pertactin</title>
        <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis pertactin. Response was defined as follows: 1) if the predose titer was &lt;4 times the lower limit of quantitation (4X LLOQ) then the postdose titer was &gt;=4X LLOQ; 2) if the predose titer was &gt;=4X LLOQ then the postdose titer was &gt;= the predose titer.</description>
        <time_frame>Postdose 4 (Month 16)</time_frame>
        <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had a vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 4.</population>
        <group_list>
          <group group_id="O1">
            <title>V419</title>
            <description>V419 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; PedvaxHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Pentacel™ 0.5 mL IM at 2, 4, and 6 months of age; Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; ActHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Responding to Pertussis Pertactin</title>
          <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis pertactin. Response was defined as follows: 1) if the predose titer was &lt;4 times the lower limit of quantitation (4X LLOQ) then the postdose titer was &gt;=4X LLOQ; 2) if the predose titer was &gt;=4X LLOQ then the postdose titer was &gt;= the predose titer.</description>
          <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had a vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 4.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="701"/>
                <count group_id="O2" value="351"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.01" lower_limit="90.86" upper_limit="94.78"/>
                    <measurement group_id="O2" value="93.45" lower_limit="90.33" upper_limit="95.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority requires that the lower limit of the 95% CI of the response rate difference is &gt;= -10%</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>Response rate, response rate difference and p-value were stratified by brand of birth dose of Hepatitis B vaccine</method_desc>
            <param_type>Response Rate Difference (V419 - Ctrl)</param_type>
            <param_value>-0.41</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.46</ci_lower_limit>
            <ci_upper_limit>3.10</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Responding to Pertussis Fimbriae</title>
        <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis fimbriae. Response was defined as follows: 1) if the predose titer was &lt;4 times the lower limit of quantitation (4X LLOQ) then the postdose titer was &gt;=4X LLOQ; 2) if the predose titer was &gt;=4X LLOQ then the postdose titer was &gt;= the predose titer.</description>
        <time_frame>Postdose 4 (Month 16)</time_frame>
        <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had a vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 4.</population>
        <group_list>
          <group group_id="O1">
            <title>V419</title>
            <description>V419 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; PedvaxHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Pentacel™ 0.5 mL IM at 2, 4, and 6 months of age; Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; ActHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Responding to Pertussis Fimbriae</title>
          <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis fimbriae. Response was defined as follows: 1) if the predose titer was &lt;4 times the lower limit of quantitation (4X LLOQ) then the postdose titer was &gt;=4X LLOQ; 2) if the predose titer was &gt;=4X LLOQ then the postdose titer was &gt;= the predose titer.</description>
          <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had a vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 4.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="700"/>
                <count group_id="O2" value="351"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.29" lower_limit="95.79" upper_limit="98.36"/>
                    <measurement group_id="O2" value="91.17" lower_limit="87.70" upper_limit="93.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority requires that the lower limit of the 95% CI of the response rate difference is &gt;= -10%</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>Response rate, response rate difference and p-value were stratified by brand of birth dose of Hepatitis B vaccine</method_desc>
            <param_type>Response Rate Difference (V419 - Ctrl)</param_type>
            <param_value>6.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.26</ci_lower_limit>
            <ci_upper_limit>9.78</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Concentration of Antibodies to Pertussis Toxin</title>
        <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis toxin.</description>
        <time_frame>Postdose 4 (Month 16)</time_frame>
        <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had an infant vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 4.</population>
        <group_list>
          <group group_id="O1">
            <title>V419</title>
            <description>V419 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; PedvaxHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Pentacel™ 0.5 mL IM at 2, 4, and 6 months of age; Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; ActHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration of Antibodies to Pertussis Toxin</title>
          <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis toxin.</description>
          <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had an infant vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 4.</population>
          <units>EU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="713"/>
                <count group_id="O2" value="356"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127.22" lower_limit="121.17" upper_limit="133.57"/>
                    <measurement group_id="O2" value="91.31" lower_limit="85.09" upper_limit="97.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority requires that the lower limit of the 2-sided 95% CI of the GMC ratio is &gt;=0.67</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>GMC, GMC ratio, and p-value were adjusted for post- and prevaccination titer, vaccination group, and brand of birth dose of Hepatitis B vaccine</method_desc>
            <param_type>GMC Ratio (V419/Control)</param_type>
            <param_value>1.40</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.28</ci_lower_limit>
            <ci_upper_limit>1.52</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Concentration of Antibodies to Pertussis Filamentous Hemagglutinin</title>
        <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis filamentous hemagglutinin.</description>
        <time_frame>Postdose 4 (Month 16)</time_frame>
        <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had an infant vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 4.</population>
        <group_list>
          <group group_id="O1">
            <title>V419</title>
            <description>V419 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; PedvaxHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Pentacel™ 0.5 mL IM at 2, 4, and 6 months of age; Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; ActHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration of Antibodies to Pertussis Filamentous Hemagglutinin</title>
          <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis filamentous hemagglutinin.</description>
          <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had an infant vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 4.</population>
          <units>EU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="710"/>
                <count group_id="O2" value="357"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.92" lower_limit="84.06" upper_limit="94.05"/>
                    <measurement group_id="O2" value="89.18" lower_limit="82.54" upper_limit="96.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority requires that the lower limit of the 2-sided 95% CI of the GMC ratio is &gt;=0.67</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>GMC, GMC ratio, and p-value were adjusted for post- and prevaccination titer, vaccination group, and brand of birth dose of Hepatitis B vaccine</method_desc>
            <param_type>GMC Ratio (V419/Control)</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>1.10</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Concentration of Antibodies to Pertussis Pertactin</title>
        <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis pertactin.</description>
        <time_frame>Postdose 4 (Month 16)</time_frame>
        <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had an infant vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 4.</population>
        <group_list>
          <group group_id="O1">
            <title>V419</title>
            <description>V419 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; PedvaxHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Pentacel™ 0.5 mL IM at 2, 4, and 6 months of age; Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; ActHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration of Antibodies to Pertussis Pertactin</title>
          <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis pertactin.</description>
          <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had an infant vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 4.</population>
          <units>EU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="713"/>
                <count group_id="O2" value="358"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108.05" lower_limit="99.88" upper_limit="116.90"/>
                    <measurement group_id="O2" value="139.35" lower_limit="124.81" upper_limit="155.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority requires that the lower limit of the 2-sided 95% CI of the GMC ratio is &gt;=0.67</non_inferiority_desc>
            <p_value>0.014</p_value>
            <method>ANCOVA</method>
            <method_desc>GMC, GMC ratio, and p-value were adjusted for post- and prevaccination titer, vaccination group, and brand of birth dose of Hepatitis B vaccine</method_desc>
            <param_type>GMC Ratio (V419/Control)</param_type>
            <param_value>0.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.68</ci_lower_limit>
            <ci_upper_limit>0.89</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Concentration of Antibodies to Pertussis Fimbriae</title>
        <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis fimbriae.</description>
        <time_frame>Postdose 4 (Month 16)</time_frame>
        <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had an infant vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 4.</population>
        <group_list>
          <group group_id="O1">
            <title>V419</title>
            <description>V419 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; PedvaxHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Pentacel™ 0.5 mL IM at 2, 4, and 6 months of age; Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; ActHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration of Antibodies to Pertussis Fimbriae</title>
          <description>Participant serum samples were collected for testing with an ELISA for antibodies to pertussis fimbriae.</description>
          <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had an infant vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 4.</population>
          <units>EU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="713"/>
                <count group_id="O2" value="358"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="658.50" lower_limit="617.53" upper_limit="702.20"/>
                    <measurement group_id="O2" value="414.66" lower_limit="371.41" upper_limit="462.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority requires that the lower limit of the 2-sided 95% CI of the GMC ratio is &gt;=0.67</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>GMC, GMC ratio, and p-value were adjusted for post- and prevaccination titer, vaccination group, and brand of birth dose of Hepatitis B vaccine</method_desc>
            <param_type>GMC Ratio (V419/Control)</param_type>
            <param_value>1.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.41</ci_lower_limit>
            <ci_upper_limit>1.78</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Concentration of Antibodies to Polyribosylribitol Phosphate Antigen</title>
        <description>Participant serum samples were collected for testing with a radioimmunoassay for antibodies to Haemophilus influenza type b capsular polysaccharide polyribosylribitol phosphate.</description>
        <time_frame>Postdose 3 (Month 7)</time_frame>
        <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had an infant vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
        <group_list>
          <group group_id="O1">
            <title>V419</title>
            <description>V419 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; PedvaxHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Pentacel™ 0.5 mL IM at 2, 4, and 6 months of age; Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; ActHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration of Antibodies to Polyribosylribitol Phosphate Antigen</title>
          <description>Participant serum samples were collected for testing with a radioimmunoassay for antibodies to Haemophilus influenza type b capsular polysaccharide polyribosylribitol phosphate.</description>
          <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had an infant vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
          <units>μg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="765"/>
                <count group_id="O2" value="382"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.11" lower_limit="4.55" upper_limit="5.73"/>
                    <measurement group_id="O2" value="3.18" lower_limit="2.66" upper_limit="3.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority requires that the lower limit of the 2-sided 95% CI of the GMC ratio is &gt;=0.67</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>GMC, GMC ratio, and p-value were adjusted for post- and prevaccination titer, vaccination group, and brand of birth dose of Hepatitis B vaccine</method_desc>
            <param_type>GMC Ratio (V419/Control)</param_type>
            <param_value>1.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.32</ci_lower_limit>
            <ci_upper_limit>1.98</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Concentration of Immunoglobulin A (IgA) Antibodies to Rotavirus</title>
        <description>Participant serum samples were collected for testing with an Enzyme-linked Immunosorbent assay for IgA antibodies to rotavirus.</description>
        <time_frame>Postdose 3 (Month 7)</time_frame>
        <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had an infant vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
        <group_list>
          <group group_id="O1">
            <title>V419</title>
            <description>V419 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; PedvaxHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Pentacel™ 0.5 mL IM at 2, 4, and 6 months of age; Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; ActHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration of Immunoglobulin A (IgA) Antibodies to Rotavirus</title>
          <description>Participant serum samples were collected for testing with an Enzyme-linked Immunosorbent assay for IgA antibodies to rotavirus.</description>
          <population>The analysis population included participants who met the inclusion criteria, were not protocol violators, had an infant vaccination window of 42 to 84 days after the previous dose, and a blood draw sample window for the endpoint of 28 to 51 days after dose 3.</population>
          <units>units/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="522"/>
                <count group_id="O2" value="274"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="278.19" lower_limit="246.99" upper_limit="313.32"/>
                    <measurement group_id="O2" value="274.46" lower_limit="232.83" upper_limit="323.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority requires that the lower limit of the 2-sided 95% CI of the GMC ratio is &gt;=0.67</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>GMC, GMC ratio, and p-value were adjusted for post- and prevaccination titer, vaccination group, and brand of birth dose of Hepatitis B vaccine</method_desc>
            <param_type>GMC Ratio (V419/Control)</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>1.24</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Reporting Solicited Injection-site or Systemic Reactions</title>
        <description>Solicited injection-site reactions: Pain, Erythema, and Swelling. Solicited systemic reactions: Pyrexia, Vomiting, Crying abnormal, Somnolence, Decreased appetite, and Irritability. Grade 3 Solicited injection site reaction: Pain, Cries when injected limb is moved or the movement of the injected limb is reduced; Erythema and Swelling, &gt;5 cm. Grade 3 Solicited systemic reactions: Pyrexia, &gt;=39.5°C (&gt;=103.1°F) rectal; Vomiting, &gt;=6 episodes per 24 hours or requiring parenteral hydration; Crying abnormal, &gt;3 hours; Somnolence, Sleeping most of the time or difficult to wake up; Decreased appetite, Refuses &gt;=3 feeds or refuses most feeds; Irritability, Inconsolable.</description>
        <time_frame>Up to 5 days after any infant vaccination (up to 6 months)</time_frame>
        <population>Participants included in these analyses were All Subjects as Treated population and were defined as all vaccinated participants with safety follow up.</population>
        <group_list>
          <group group_id="O1">
            <title>V419</title>
            <description>V419 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; PedvaxHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Pentacel™ 0.5 mL IM at 2, 4, and 6 months of age; Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; ActHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Solicited Injection-site or Systemic Reactions</title>
          <description>Solicited injection-site reactions: Pain, Erythema, and Swelling. Solicited systemic reactions: Pyrexia, Vomiting, Crying abnormal, Somnolence, Decreased appetite, and Irritability. Grade 3 Solicited injection site reaction: Pain, Cries when injected limb is moved or the movement of the injected limb is reduced; Erythema and Swelling, &gt;5 cm. Grade 3 Solicited systemic reactions: Pyrexia, &gt;=39.5°C (&gt;=103.1°F) rectal; Vomiting, &gt;=6 episodes per 24 hours or requiring parenteral hydration; Crying abnormal, &gt;3 hours; Somnolence, Sleeping most of the time or difficult to wake up; Decreased appetite, Refuses &gt;=3 feeds or refuses most feeds; Irritability, Inconsolable.</description>
          <population>Participants included in these analyses were All Subjects as Treated population and were defined as all vaccinated participants with safety follow up.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="981"/>
                <count group_id="O2" value="484"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any injection-site pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.4"/>
                    <measurement group_id="O2" value="71.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 injection-site pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9"/>
                    <measurement group_id="O2" value="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any injection-site erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.8"/>
                    <measurement group_id="O2" value="42.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 injection-site erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2"/>
                    <measurement group_id="O2" value="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any injection-site swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.1"/>
                    <measurement group_id="O2" value="34.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 injection-site swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3"/>
                    <measurement group_id="O2" value="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any pyrexia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.4"/>
                    <measurement group_id="O2" value="34.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 pyrexia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5"/>
                    <measurement group_id="O2" value="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.7"/>
                    <measurement group_id="O2" value="21.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4"/>
                    <measurement group_id="O2" value="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any crying abnormal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.8"/>
                    <measurement group_id="O2" value="72.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 crying abnormal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9"/>
                    <measurement group_id="O2" value="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any somnolence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.1"/>
                    <measurement group_id="O2" value="71.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 somnolence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5"/>
                    <measurement group_id="O2" value="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any decreased appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.9"/>
                    <measurement group_id="O2" value="43.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 decreased appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3"/>
                    <measurement group_id="O2" value="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.1"/>
                    <measurement group_id="O2" value="81.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7"/>
                    <measurement group_id="O2" value="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Reporting One or More Solicited Adverse Events Related to Study Drug</title>
        <description>Solicited systemic adverse events: pyrexia, vomiting, crying abnormal, somnolence, decreased appetite, and irritability. Adverse events deemed related to study drug were those judged to be definitely related, probably related, or possibly related by the investigator.</description>
        <time_frame>Up to 5 days after any infant vaccination (up to 6 months)</time_frame>
        <population>Participants included in this analyses were All Subjects as Treated population and were defined as all vaccinated participants with safety follow up.</population>
        <group_list>
          <group group_id="O1">
            <title>V419</title>
            <description>V419 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; PedvaxHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Pentacel™ 0.5 mL IM at 2, 4, and 6 months of age; Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; ActHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting One or More Solicited Adverse Events Related to Study Drug</title>
          <description>Solicited systemic adverse events: pyrexia, vomiting, crying abnormal, somnolence, decreased appetite, and irritability. Adverse events deemed related to study drug were those judged to be definitely related, probably related, or possibly related by the investigator.</description>
          <population>Participants included in this analyses were All Subjects as Treated population and were defined as all vaccinated participants with safety follow up.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="981"/>
                <count group_id="O2" value="484"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any pyrexia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.1"/>
                    <measurement group_id="O2" value="32.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.8"/>
                    <measurement group_id="O2" value="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any crying abnormal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.4"/>
                    <measurement group_id="O2" value="68.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any somnolence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.5"/>
                    <measurement group_id="O2" value="66.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any decreased appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.7"/>
                    <measurement group_id="O2" value="40.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.6"/>
                    <measurement group_id="O2" value="77.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Reporting One or More Solicited Adverse Events Related to Study Drug</title>
        <description>Solicited systemic adverse events: pyrexia, vomiting, crying abnormal, somnolence, decreased appetite, and irritability. Adverse events deemed related to study drug were those judged to be definitely related, probably related, or possibly related by the investigator.</description>
        <time_frame>Up to 5 days after each infant vaccination (up to 6 months)</time_frame>
        <population>Participants included in this analyses were All Subjects as Treated population and were defined as all vaccinated participants with safety follow up.</population>
        <group_list>
          <group group_id="O1">
            <title>V419</title>
            <description>V419 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; PedvaxHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Pentacel™ 0.5 mL IM at 2, 4, and 6 months of age; Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; ActHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting One or More Solicited Adverse Events Related to Study Drug</title>
          <description>Solicited systemic adverse events: pyrexia, vomiting, crying abnormal, somnolence, decreased appetite, and irritability. Adverse events deemed related to study drug were those judged to be definitely related, probably related, or possibly related by the investigator.</description>
          <population>Participants included in this analyses were All Subjects as Treated population and were defined as all vaccinated participants with safety follow up.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="981"/>
                <count group_id="O2" value="484"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any pyrexia, vaccination 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.1"/>
                    <measurement group_id="O2" value="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any pyrexia, vaccination 2 (N=950, 472)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.6"/>
                    <measurement group_id="O2" value="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any pyrexia, vaccination 3 (N=924, 460)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.6"/>
                    <measurement group_id="O2" value="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any vomiting, vaccination 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.2"/>
                    <measurement group_id="O2" value="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any vomiting, vaccination 2 (N=950, 472)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2"/>
                    <measurement group_id="O2" value="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any vomiting, vaccination 3 (N=924, 460)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0"/>
                    <measurement group_id="O2" value="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any crying abnormal, vaccination 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.9"/>
                    <measurement group_id="O2" value="48.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any crying abnormal, vaccination 2 (N=950, 472)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.4"/>
                    <measurement group_id="O2" value="42.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any crying abnormal, vaccination 3 (N=924, 460)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.0"/>
                    <measurement group_id="O2" value="36.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any somnolence, vaccination 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.6"/>
                    <measurement group_id="O2" value="54.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any somnolence, vaccination 2 (N=950, 472)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.9"/>
                    <measurement group_id="O2" value="41.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any somnolence, vaccination 3 (N=924, 460)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.3"/>
                    <measurement group_id="O2" value="35.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any decreased appetite, vaccination 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.4"/>
                    <measurement group_id="O2" value="24.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any decreased appetite, vaccination 2 (N=950, 472)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.1"/>
                    <measurement group_id="O2" value="19.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any decreased appetite, vaccination 3 (N=924, 460)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.9"/>
                    <measurement group_id="O2" value="17.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any irritability, vaccination 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.2"/>
                    <measurement group_id="O2" value="60.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any irritability, vaccination 2 (N=950, 472)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.6"/>
                    <measurement group_id="O2" value="52.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any irritability, vaccination 3 (N=924, 460)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.7"/>
                    <measurement group_id="O2" value="48.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Elevated Temperature by Severity</title>
        <description>Maximum temperature (all routes) was based on actual temperatures recorded with no adjustments to the measurement route. Maximum temperature (rectal) was required of all participants if the reading by another method was &gt;=38.0°C.</description>
        <time_frame>Up to 5 days after any infant vaccination (up to 6 months)</time_frame>
        <population>Participants included in this analyses were All Subjects as Treated population and were defined as all vaccinated participants with safety follow up and temperature data.</population>
        <group_list>
          <group group_id="O1">
            <title>V419</title>
            <description>V419 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; PedvaxHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Pentacel™ 0.5 mL IM at 2, 4, and 6 months of age; Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; ActHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Elevated Temperature by Severity</title>
          <description>Maximum temperature (all routes) was based on actual temperatures recorded with no adjustments to the measurement route. Maximum temperature (rectal) was required of all participants if the reading by another method was &gt;=38.0°C.</description>
          <population>Participants included in this analyses were All Subjects as Treated population and were defined as all vaccinated participants with safety follow up and temperature data.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="981"/>
                <count group_id="O2" value="484"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All routes &lt;38.0°C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.1"/>
                    <measurement group_id="O2" value="64.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All routes &gt;=38.0°C and &lt;38.5°C, mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.2"/>
                    <measurement group_id="O2" value="19.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All routes &gt;=38.5°C and &lt;39.5°C, moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.7"/>
                    <measurement group_id="O2" value="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All routes &gt;=39.5°C, severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                    <measurement group_id="O2" value="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rectal &lt;38.0°C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.5"/>
                    <measurement group_id="O2" value="57.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rectal &gt;=38.0°C and &lt;38.5°C, mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.3"/>
                    <measurement group_id="O2" value="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rectal &gt;=38.5°C and &lt;39.5°C, moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.6"/>
                    <measurement group_id="O2" value="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rectal &gt;=39.5°C, severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                    <measurement group_id="O2" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Estimated difference, all routes &lt;38°C</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-13.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.4</ci_lower_limit>
            <ci_upper_limit>-7.7</ci_upper_limit>
            <estimate_desc>Mean Difference is V419 - Control. The 95% confidence intervals were based on the unstratified Miettinen and Nurminen method.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Estimated difference, all routes &gt;=38°C and &lt;38.5°C</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.5</ci_lower_limit>
            <ci_upper_limit>9.5</ci_upper_limit>
            <estimate_desc>Mean Difference is V419 - Control. The 95% confidence intervals were based on the unstratified Miettinen and Nurminen method.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Estimated difference, all routes &gt;=38.5°C and &lt;39.5°C</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>7.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.8</ci_lower_limit>
            <ci_upper_limit>11.2</ci_upper_limit>
            <estimate_desc>Mean Difference is V419 - Control. The 95% confidence intervals were based on the unstratified Miettinen and Nurminen method.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Estimated difference, all routes &gt;=39.5°C</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6</ci_lower_limit>
            <ci_upper_limit>2.2</ci_upper_limit>
            <estimate_desc>Mean Difference is V419 - Control. The 95% confidence intervals were based on the unstratified Miettinen and Nurminen method.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Estimated difference, rectal &lt;38°C</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-13.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.6</ci_lower_limit>
            <ci_upper_limit>-7.7</ci_upper_limit>
            <estimate_desc>Mean Difference is V419 - Control. The 95% confidence intervals were based on the unstratified Miettinen and Nurminen method.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Estimated difference, rectal &gt;=38°C and &lt;38.5°C</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.9</ci_lower_limit>
            <ci_upper_limit>10.8</ci_upper_limit>
            <estimate_desc>Mean Difference is V419 - Control. The 95% confidence intervals were based on the unstratified Miettinen and Nurminen method.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Estimated difference, rectal &gt;=38.5°C and &lt;39.5°C</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.4</ci_lower_limit>
            <ci_upper_limit>10.7</ci_upper_limit>
            <estimate_desc>Mean Difference is V419 - Control. The 95% confidence intervals were based on the unstratified Miettinen and Nurminen method.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Estimated difference, rectal &gt;=39.5°C</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.3</ci_lower_limit>
            <ci_upper_limit>2.4</ci_upper_limit>
            <estimate_desc>Mean Difference is V419 - Control. The 95% confidence intervals were based on the unstratified Miettinen and Nurminen method.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Pyrexia, Febrile Convulsion, or Convulsion</title>
        <description>The percentage of participants with one or more adverse events (AE), serious adverse events (SAE), and vaccine-related SAE (pyrexia, febrile convulsion, and convulsion) is reported.</description>
        <time_frame>Up to 15 days after any infant vaccination (up to 6 months)</time_frame>
        <population>Participants included in this analyses were All Subjects as Treated population and were defined as all vaccinated participants with safety follow up.</population>
        <group_list>
          <group group_id="O1">
            <title>V419</title>
            <description>V419 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; PedvaxHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Pentacel™ 0.5 mL IM at 2, 4, and 6 months of age; Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; ActHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Pyrexia, Febrile Convulsion, or Convulsion</title>
          <description>The percentage of participants with one or more adverse events (AE), serious adverse events (SAE), and vaccine-related SAE (pyrexia, febrile convulsion, and convulsion) is reported.</description>
          <population>Participants included in this analyses were All Subjects as Treated population and were defined as all vaccinated participants with safety follow up.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="981"/>
                <count group_id="O2" value="484"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pyrexia AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.3"/>
                    <measurement group_id="O2" value="35.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Febrile convulsion AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Convulsion AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pyrexia SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Febrile convulsion SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Convulsion SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Pyrexia, Febrile Convulsion, or Convulsion</title>
        <description>The percentage of participants with one or more adverse events (AE), serious adverse events (SAE), and vaccine-related SAE (pyrexia, febrile convulsion, and convulsion) is reported.</description>
        <time_frame>Up to 181 days after any infant vaccination (up to 12 months)</time_frame>
        <population>Participants included in this analyses were All Subjects as Treated population and were defined as all vaccinated participants with safety follow up.</population>
        <group_list>
          <group group_id="O1">
            <title>V419</title>
            <description>V419 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; PedvaxHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Pentacel™ 0.5 mL IM at 2, 4, and 6 months of age; Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; ActHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Pyrexia, Febrile Convulsion, or Convulsion</title>
          <description>The percentage of participants with one or more adverse events (AE), serious adverse events (SAE), and vaccine-related SAE (pyrexia, febrile convulsion, and convulsion) is reported.</description>
          <population>Participants included in this analyses were All Subjects as Treated population and were defined as all vaccinated participants with safety follow up.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="981"/>
                <count group_id="O2" value="484"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pyrexia SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Febrile convulsion SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Convulsion SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1"/>
                    <measurement group_id="O2" value="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pyrexia vaccine-related SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Febrile convulsion vaccine-related SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Convulsion vaccine-related SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>SAEs: up to 6 months after vaccination 3 (the last infant vaccination) and up to 15 days after vaccination 4 (the toddler vaccination); Vaccine-related SAEs and deaths: up to Month 16 (duration of the study); Other AEs: up to 15 days after any vaccination</time_frame>
      <desc>The All Subjects as Treated population included all randomized participants who received at least one dose of study vaccine and had safety follow-up</desc>
      <group_list>
        <group group_id="E1">
          <title>V419</title>
          <description>V419 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; PedvaxHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>Pentacel™ 0.5 mL IM at 2, 4, and 6 months of age; Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; ActHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="980"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="483"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="980"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="980"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="483"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="980"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="483"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Pyloric stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="980"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="483"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="980"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="980"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="980"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="483"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Device expulsion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="980"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="980"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="483"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="980"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="980"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="980"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Croup infectious</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="980"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Gastritis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="980"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="980"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Gastroenteritis salmonella</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="980"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="980"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Human herpesvirus 6 infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="980"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="980"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Meningitis enteroviral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="980"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Meningitis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="980"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="980"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="980"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="980"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus bronchiolitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="980"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="980"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Roseola</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="980"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="980"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="980"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="980"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="980"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Vulval abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="980"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Wound infection staphylococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="980"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="483"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="980"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Foreign body</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="980"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="980"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Post concussion syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="980"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="980"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Skull fracture base</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="980"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="980"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="483"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Urine output decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="980"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="483"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal weight gain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="980"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="980"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="980"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="980"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="483"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="980"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Dyskinesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="980"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Dystonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="980"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="980"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Movement disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="980"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Tonic convulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="980"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="483"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="980"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="483"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Apparent life threatening event</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="980"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Asphyxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="980"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="980"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="980"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Bronchial hyperreactivity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="980"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="980"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="980"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Infantile apnoeic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="980"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="980"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="980"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="980"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="980"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="483"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Kawasaki's disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="980"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="483"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="939" subjects_at_risk="980"/>
                <counts group_id="E2" subjects_affected="458" subjects_at_risk="483"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="68" subjects_affected="61" subjects_at_risk="980"/>
                <counts group_id="E2" events="25" subjects_affected="22" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="432" subjects_affected="282" subjects_at_risk="980"/>
                <counts group_id="E2" events="186" subjects_affected="125" subjects_at_risk="483"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Crying</sub_title>
                <counts group_id="E1" events="1933" subjects_affected="788" subjects_at_risk="980"/>
                <counts group_id="E2" events="857" subjects_affected="370" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="2389" subjects_affected="853" subjects_at_risk="980"/>
                <counts group_id="E2" events="1109" subjects_affected="415" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1014" subjects_affected="560" subjects_at_risk="980"/>
                <counts group_id="E2" events="356" subjects_affected="216" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Injection-site bruising</sub_title>
                <counts group_id="E1" events="103" subjects_affected="62" subjects_at_risk="980"/>
                <counts group_id="E2" events="61" subjects_affected="36" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Injection-site erythema</sub_title>
                <counts group_id="E1" events="2665" subjects_affected="597" subjects_at_risk="980"/>
                <counts group_id="E2" events="1365" subjects_affected="277" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Injection-site pain</sub_title>
                <counts group_id="E1" events="4276" subjects_affected="826" subjects_at_risk="980"/>
                <counts group_id="E2" events="2234" subjects_affected="391" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Injection-site swelling</sub_title>
                <counts group_id="E1" events="1974" subjects_affected="513" subjects_at_risk="980"/>
                <counts group_id="E2" events="989" subjects_affected="219" subjects_at_risk="483"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="76" subjects_affected="69" subjects_at_risk="980"/>
                <counts group_id="E2" events="28" subjects_affected="26" subjects_at_risk="483"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="108" subjects_affected="100" subjects_at_risk="980"/>
                <counts group_id="E2" events="41" subjects_affected="40" subjects_at_risk="483"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="1087" subjects_affected="577" subjects_at_risk="980"/>
                <counts group_id="E2" events="469" subjects_affected="271" subjects_at_risk="483"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="1863" subjects_affected="755" subjects_at_risk="980"/>
                <counts group_id="E2" events="887" subjects_affected="369" subjects_at_risk="483"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/ presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

